Opportunistic infections due to inflammatory bowel disease therapy.
about
Oral pathology in inflammatory bowel diseaseThe relationship between intestinal parasites and some immune-mediated intestinal conditionsDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabDifferential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectivesMesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease.Fungal Signature in the Gut Microbiota of Pediatric Patients With Inflammatory Bowel Disease.The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: a state of the science review.Spray-drying process preserves the protective capacity of a breast milk-derived Bifidobacterium lactis strain on acute and chronic colitis in mice.Managing Clostridium difficile in inflammatory bowel disease (IBD).Long-term safety of immunomodulators in pediatric inflammatory diseases.Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease: A Practical Case-based Approach.Adalimumab for the treatment of pediatric Crohn's disease.Inflammatory Bowel Disease: Predictors and Causes of Early and Late Hospital Readmissions.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.The safety of vedolizumab for ulcerative colitis and Crohn's disease.The first study on opportunistic intestinal microsporidiosis in IBD patients receiving immunosuppressive medications in Iran.Genetic risk factors for serious infections in inflammatory bowel diseases.Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.Posterior Reversible Encephalopathy Syndrome and Fatal Cryptococcal Meningitis After Immunosuppression in a Patient With Elderly Onset Inflammatory Bowel Disease.Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis.Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial.Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease: A Nationwide Danish Cohort Study 1977-2013.Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study.Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents.The Inflammatory Bowel Disease Specialty Medical Home: A New Model of Patient-centered Care.Ultra-small solid archaeolipid nanoparticles for active targeting to macrophages of the inflamed mucosa.Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease
P2860
Q26739055-87993782-825C-4786-B8A3-18A89B7B6A22Q26830491-36E796A2-566B-452C-8394-1F71F02797A1Q28083872-BBBC02FC-46B6-491E-B7F1-C13015B5E7AFQ28085134-90B06992-1256-4542-8D1F-783580BFB858Q34487787-0132976F-34D4-4622-8917-74B7732C6D5EQ35028459-8007E613-6FDB-42A5-87CC-881F6F5CB2AEQ35271319-A921BB91-14B0-4B70-9736-3DB65B4378CDQ35666254-D0125EC2-2A11-481D-8A39-8CD530925C3CQ36153323-EA5A4872-D3EB-4D97-8628-BAB8F1EF9E36Q37663156-29A57B63-203B-4365-AB94-FFF4C34A923BQ38212583-F764FA05-CD79-4640-8500-1BB197CB3F3DQ38232338-533180B8-BBA7-46A1-ADAC-DDE1C085A810Q38475865-165F17D2-BB1C-45BD-ADCA-9BFF1D794B0EQ38554433-388719F2-0A98-460E-BEB4-D560FFD1CF9EQ38635051-BDCBC54C-35E4-4B2C-80A6-B20F56AAAC3BQ38652276-0E8AABE0-C5DA-4259-B7D8-2765458A0822Q39025057-751A6060-BCCC-49F5-9059-4CFDC9AAA587Q39435409-25D347A1-203C-4760-87F0-C9D7FC1B9A7DQ39985219-03F90158-E8DB-458C-B20B-ADF9353B61A7Q40202230-E9DEA7EF-EF6A-455B-87C5-6FF503F41E07Q40344947-3471DA8B-EF09-4327-83B2-E21E2443247FQ40396288-7CC6A8C6-0951-4B15-A76A-2027BF88D0E9Q40468279-1688709C-B4E3-48C2-9936-F2773E13733FQ40564307-DEB25369-4C26-4B61-8120-0599F17B3BFEQ40879326-101E8DD8-E156-4AB1-8050-F0D40C6C4862Q41011615-AA231C2C-1ABA-4706-87EC-34BA7AF4FC70Q41680666-F75CD47E-416B-4DA8-96A8-56DF98FE16FDQ44513014-1B87427F-0A99-40A6-B24A-FDF222017F93Q48056630-8CAB9D94-5A2C-49AB-98D6-160F42D8052AQ51032601-23B54071-76DD-406A-ACFC-B91806404983Q57284272-15D13E4E-6888-420A-8FEC-96B54C2441B6
P2860
Opportunistic infections due to inflammatory bowel disease therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Opportunistic infections due to inflammatory bowel disease therapy.
@en
type
label
Opportunistic infections due to inflammatory bowel disease therapy.
@en
prefLabel
Opportunistic infections due to inflammatory bowel disease therapy.
@en
P2093
P2860
P1476
Opportunistic infections due to inflammatory bowel disease therapy.
@en
P2093
Maneesh Dave
Raymund Razonable
Treta Purohit
P2860
P304
P356
10.1097/MIB.0B013E3182A827D2
P577
2014-01-01T00:00:00Z